The Discounted Cash Flow (DCF) valuation of BioCryst Pharmaceuticals Inc (BCRX) is (6.13) USD. With the latest stock price at 10.08 USD, the upside of BioCryst Pharmaceuticals Inc based on DCF is -160.9%.
Based on the latest price of 10.08 USD and our DCF valuation, BioCryst Pharmaceuticals Inc (BCRX) is a sell. selling BCRX stocks now will result in a potential gain of 160.9%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.2% - 9.6% | 7.9% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (11.69) - (5.12) | (6.13) |
| Upside | -215.9% - -150.8% | -160.9% |